This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
3 April – NASA selects three companies – Intuitive Machines, Lunar Outpost and Venturi Astrolab – to develop its Lunar Terrain Vehicle, for use in crewed Artemis missions from 2030 onwards. 4 April A study in Nature finds that global CO2 emissions increased by only 0.1% in 2023, suggesting that a plateau may have been reached. The Dark Energy Spectroscopic Instrument (DESI) project releases multiple papers which report unprecedented measurements of dark energy, find indications that dark energy which is expanding the Universe is evolving over time, and release the most detailed largest 3D cosmic map to date. 5 April – A numerical toolkit designed for modelling warp drive spacetimes is introduced in Classical and Quantum Gravity. 9 April – A rare genetic variation in a gene that makes fibronectin is shown to reduce the odds of developing Alzheimer's disease by over 70%. 11 April – The first nitrogen-fixing organelle in a marine alga is reported, the nitroplast. The early evolutionary stage organelle provides a view into the transition from an endosymbiont into a proper organelle that receives about half of its proteins from the alga. 12 April Biologists report that bonobos behave more aggressively than thought earlier. Scientists describe how tardigrades are protecting themselves from large radiation exposure and damage, which is quickly repaired, using the Dsup protein. 15 April The NOAA confirms a fourth global coral bleaching event. The world's first commercial-scale factory producing sustainable high-protein food from air, microbes and solar energy, Solein, launches.
These attempts were unsuccessful, but presaged the use of hydroxyurea as a treatment modality. In addition, Beutler designed the first artificial storage media for red blood cells, introduced the use of mannitol (still a mainstay in red cell preservation), and devised a variety of approaches to maintaining red cell ATP and 2,3-DPG levels and determined the viability of the cells in human volunteers. He also played a major role in pioneering new therapies for leukemia: bone marrow transplantation in acute leukemia, and 2-chorodeoxyadenosine in chronic leukemias and lymphomas. Beginning in the mid-1990s, Beutler attempted to positionally clone the mutation responsible for the common adult-onset form of hereditary hemochromatosis. He failed to identify the mutation before it was found by others to affect HFE, a member of the major histocompatibility complex family of proteins. However, in contrast to the reports of others, he found that only about 2% of males and no females homozygous for the mutation showed severe clinical manifestations of the disease. This study depended upon genotypic and phenotypic analysis of more than 43,000 subjects. Beutler served as an editor of Williams Hematology, a widely used text in this medical specialty, for more than 20 years: from its inception until the last year of his life. In keeping with his editorial interests and his requirements as a publishing scientist, Beutler also wrote the software for the first comprehensive bibliographic retrieval system used by publishing scientists.
=== Multiple turns === In many cases, one or more residues are involved in two partially overlapping turns. For example, in a sequence of 5 residues, both residues 1 to 4 and residues 2 to 5 form a turn; in such a case, one speaks of an (i, i + 1) double turn. Multiple turns (up to sevenfold) occur commonly in proteins. Beta bend ribbons are a different type of multiple turn. Multiple types of short H-bonded loop motifs are composed of overlapping H-bonded turns of the same or different types (lengths), including the Schellman loop and its variants, the multiple types of the beta bulge loop, and others. These motifs, which play key roles in proteins, including as helix caps, chain-reversers in beta hairpins and ligand binders, have been described as "compound turns" and classified using a compact notation that specifies the types and start positions in the loop of each motif's turns. The ExploreTurns tool supports the exploration and analysis of these motifs. The tool may also be used to explore individual H-bonded turns of all types.
Sources: en.wikipedia.org
He claimed that his own studies had shown that up to 1 in 10 of hypoglycaemia episodes in elderly people were caused naturally. Marks said the four patients picked out by the experts after Mrs Hall's death "were all at very high risk of developing spontaneous hypoglycaemia" because they had risk factors such as malnutrition, infection and multi-organ failure. In 2011 Louise Shorter, the former producer of BBC's Rough Justice, and journalist Mark Daly produced the documentary A Jury in the Dark, arguing that there were logical, non-criminal explanations for all the deaths. They and Marks claimed that Ethel Hall's hypoglycaemic arrest could have been caused naturally by 'auto-immune syndrome'. The possibility of auto-immune syndrome having caused the women's arrests had also already been considered and rejected at the trial. During research for the film, Daly discovered an additional death at Leeds General Infirmary which police had initially been investigating as a potential murder carried out by a male nurse, however; the death "went from suspicious to non-suspicious", when police learned that Norris was not on duty at the time. Norris's mother has tried to prove her son innocent, saying: "Either I am the mother of Scotland's worst serial killer or mother to the victim of the country's most terrible miscarriage of justice". After watching the BBC programme the sister-in-law of victim Bridget Bourke said that she was still convinced of Norris's guilt.
== Distribution == The royal angelfish is widely distributed throughout the Indo-Pacific. The species can be found in the Red Sea and Indian Ocean around East Africa and the Maldives, stretching to the Tuamoto Islands, New Caledonia, and Great Barrier Reef. The northernmost limits of its range ends in the southern East China Sea around Taiwan and the Ryukyu Islands and Ogasawara Islands of Japan.
Aurélia Nguyen is a French-Vietnamese public health official, and the current Deputy Chief Executive Officer of CEPI (Coalition for Epidemic Preparedness Innovations)[1]. She previously was the managing director of the COVAX Facility at Gavi (formerly Global Alliance for Vaccines and Immunization.). In her role at COVAX, she works on providing COVID-19 vaccines to lower income countries, and tackling issues such as vaccine diplomacy, exports controls, limited supplies and cold-chain logistics.
Zinc has an electron configuration of [Ar]4s23d10 and is a member of the group 12 of the periodic table. It is a moderately reactive metal and strong reducing agent; in the reactivity series it is comparable to manganese. The surface of the pure metal tarnishes quickly, eventually forming a protective passivating layer of the basic zinc carbonate, Zn5(OH)6(CO3)2, by reaction with atmospheric carbon dioxide. Zinc burns in air with a bright bluish-green flame, giving off fumes of zinc oxide. Zinc reacts readily with acids, alkalis and other non-metals. Extremely pure zinc reacts only slowly at room temperature with acids. Strong acids, such as hydrochloric or sulfuric acid, can remove the passivating layer and the subsequent reaction with the acid releases hydrogen gas. Zinc chemistry resembles that of the late first-row transition metals, nickel and copper, as well as certain main-group elements. Almost all zinc compounds have the element in the +2 oxidation state. When Zn2+ compounds form, the outer shell s electrons are lost, yielding a bare zinc ion with the electronic configuration [Ar]3d10. The filled interior d shell generally does not participate in bonding, producing diamagnetic and mostly colorless compounds. In aqueous solution an octahedral complex, [Zn(H2O)6]2+ is the predominant species. The ionic radii of zinc and magnesium happen to be nearly identical.
Sources: en.wikipedia.org
Kyle Hardingham (born 1 September 1988) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Hardingham was selected by Essendon with the seventh pick in the 2010 AFL Pre-Season Draft. Originally from East Fremantle in the WAFL, he represented Western Australia in the state game against South Australia in 2009. He made his AFL debut against North Melbourne in round 17 of the 2010 AFL season, kicking four goals, helping Essendon achieve an upset victory by 3 points. The following Friday night, he kicked two goals in a win against St Kilda. He managed to kick two goals once again in the next game, a 76-point loss to Carlton, although he also kicked two behinds as part of the wayward kicking by the entire Essendon team, which managed 9.19 for the night. Hardingham was delisted at the conclusion of the 2014 AFL season. He remained with Essendon as a VFL-listed player in its reserves team in 2016. Hardingham, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 season.
Research or investigator INDs are non-commercial INDs filed by researchers to study an unapproved drug or to study an approved drug for a new indication or in a new patient population. Emergency Use INDs, also called compassionate use or single-patient INDs, are filed for emergency use of an unapproved drug when the clinical situation does not allow sufficient time to submit an IND in accordance with 21 CFR §§ 312.23, 312.24. These are most commonly used for life-threatening conditions for which there is no standard treatment. Treatment INDs are filed to make a drug available for the treatment of serious or immediately life-threatening conditions prior to FDA approval. Serious diseases or conditions are stroke, schizophrenia, rheumatoid arthritis, osteoarthritis, chronic depression, seizures, Alzheimer's dementia, amyotrophic lateral sclerosis (ALS), and narcolepsy. Screening INDs are filed for multiple, closely related compounds in order to screen for the preferred compounds or formulations. The preferred compound can then be developed under a separate IND. Used for screening different salts, esters and other drug derivatives that are chemically different, but pharmacodynamically similar.
== Nomenclature and terminology == The nomenclature of the metal carbonyls depends on the charge of the complex, the number and type of central atoms, and the number and type of ligands and their binding modes. They occur as neutral complexes, as positively-charged metal carbonyl cations or as negatively charged metal carbonylates. The carbon monoxide ligand may be bound terminally to a single metal atom or bridging to two or more metal atoms. These complexes may be homoleptic, containing only CO ligands, such as nickel tetracarbonyl (Ni(CO)4), but more commonly metal carbonyls are heteroleptic and contain a mixture of ligands. Mononuclear metal carbonyls contain only one metal atom as the central atom. Except vanadium hexacarbonyl, only metals with even atomic number, such as chromium, iron, nickel, and their homologs, build neutral mononuclear complexes. Polynuclear metal carbonyls are formed from metals with odd atomic numbers and contain a metal–metal bond. Complexes with different metals but only one type of ligand are called isoleptic. Carbon monoxide has distinct binding modes in metal carbonyls. They differ in terms of their hapticity, denoted η, and their bridging mode. In η2-CO complexes, both the carbon and oxygen are bonded to the metal. More commonly only carbon is bonded, in which case the hapticity is not mentioned. The carbonyl ligand engages in a wide range of bonding modes in metal carbonyl dimers and clusters. In the most common bridging mode, denoted μ2 or simply μ, the CO ligand bridges a pair of metals.
== Adverse effects == The most common adverse drug reactions (ADRs) are dose-related and arise from the effect of loop diuretics on diuresis and electrolyte balance. Common ADRs include: hyponatremia, hypokalemia, hypomagnesemia, dehydration, hyperuricemia, gout, dizziness, postural hypotension, syncope. The loss of magnesium as a result of loop diuretics has also been suggested as a possible cause of pseudogout (chondrocalcinosis). Infrequent ADRs include: dyslipidemia, increased serum creatinine concentration, hypocalcemia, rash. Metabolic alkalosis may also be seen with loop diuretic use. Ototoxicity (damage to the inner ear) is a serious, but rare ADR associated with use of loop diuretics. This may be limited to tinnitus and vertigo, but may result in deafness in serious cases. Loop diuretics may also precipitate kidney failure in patients concurrently taking an NSAID and an ACE inhibitor—the so-called "triple whammy" effect. Because furosemide, torsemide and bumetanide are technically sulfa drugs, there is a theoretical risk that patients sensitive to sulfonamides may be sensitive to these loop diuretics. This risk is stated on drug packaging inserts. However, the actual risk of crossreactivity is largely unknown and there are some sources that dispute the existence of such cross reactivity. In one study it was found that only 10% of patients with allergy to antibiotic sulfonamides were also allergic to diuretic sulfonamides, but it is unclear if this represents true cross reactivity or the nature of being prone to allergy.
(Another possibility is assignment to a metastable isomeric state, 283mCn.) While later cross-bombardments in the 242Pu+48Ca and 245Cm+48Ca reactions succeeded in confirming the properties of 283Cn and its parents 287Fl and 291Lv, and played a major role in the acceptance of the discoveries of flerovium and livermorium (elements 114 and 116) by the JWP in 2011, this work originated subsequent to the GSI's work on 277Cn and priority was assigned to the GSI. The IUPAC/IUPAP Joint Working Party (JWP) assessed the claim of copernicium's discovery by the GSI team in 2001 and 2003. In both cases, they found that there was insufficient evidence to support their claim. This was primarily related to the contradicting decay data for the known nuclide rutherfordium-261. However, between 2001 and 2005, the GSI team studied the reaction 248Cm(26Mg,5n)269Hs, and were able to confirm the decay data for hassium-269 and rutherfordium-261. It was found that the existing data on rutherfordium-261 was for an isomer, now designated rutherfordium-261m. In May 2009, the JWP reported on the claims of discovery of element 112 again and officially recognized the GSI team as the discoverers of element 112. This decision was based on the confirmation of the decay properties of daughter nuclei as well as the confirmatory experiments at RIKEN.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.